Search results
Allspring Global Investments Holdings LLC Buys 1,191 Shares of UroGen Pharma Ltd. (NASDAQ:URGN)
ETF DAILY NEWS· 20 hours agoAllspring Global Investments Holdings LLC lifted its stake in UroGen Pharma Ltd. (NASDAQ:URGN – Free Report) by 31.6% in the 4th quarter, according to the ...
Medison Pharma and Alnylam Pharmaceuticals Announce Expansion of their Multi-Regional Partnership in...
WFRV 5 Green Bay· 14 hours ago(Nasdaq: ALNY), the leading RNAi therapeutics company, announced today a further expansion...
Japan's Ono Pharma says $2.4 bln Deciphera purchase 'first step' for global expansion
Reuters via Yahoo Finance· 17 hours agoWith this deal, Ono Pharma joins Japanese rivals Takeda Pharmaceutical and Astellas Pharma which have spent big recently to replenish their drug pipelines ...
Ex-McKinsey partner claims he was made opioids ‘scapegoat’ in suit against firm
New York Post· 1 day agoA former McKinsey & Co partner has sued the global consulting firm, claiming it defamed him and made...
ARS Pharma submits response to EMA for neffy approval By Investing.com
Investing.com· 9 hours agoARS Pharmaceuticals, Inc. (NASDAQ: SPRY) has submitted its response to the European Medicines...
Poolbeg Pharma PLC Announces Results for the Year Ended 31 December 2023
Digital Journal· 17 hours ago...Cathal Friel, Co-Founder and significant shareholder, assumed the role of Executive Chairman Jeremy Skillington, PhD, Chief Executive Officer of Poolbeg Pharma, commented: "We made excellent progress and hit multiple key milestones in 2023, the most important of all perhaps was filing patent...
Geodis obtains IATA CEIV Pharma certification for its Copenhagen hub - The Loadstar
The Loadstar· 1 day agoGEODIS now has a total of 28 CEIV Pharma certified sites across its global network in the Americas,...
ASCO 2024 | Ascentage Pharma to Present Four Studies, Including an Oral Report Featuring the Latest...
FOX21 Colorado Springs· 6 days agoAscentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancer, chronic hepatitis B (CHB), and age-related ...
Earnings call: Astellas Pharma exceeds revenue forecast, faces profit dip By Investing.com
Investing.com· 1 day agoAstellas Pharma Inc. (ALPMY) reported a surpassing of its full-year revenue forecast for FY 2023,...
Deloitte's 14th Annual Pharmaceutical Innovation Report: Pharma R&D Return on Investment Rebounds...
WKBN 27 Youngstown· 6 days agoProjected return on investment in pharma research and development (R&D) in 2023 has risen to 4.1%, climbing back from 2022's record low of 1.2%. Total sales revenue for the ...